EMERYVILLE, Calif. -- (BUSINESS WIRE) -- KineMed, Inc. (www.kinemed.com) today announced an agreement with EMD Serono to apply KineMed’s mass spectrometric Dynamic Proteomics and lipids platforms to the discovery of protein and lipid biomarkers for multiple sclerosis.
Myelin breakdown and synthesis is a fundamental process underlying progression and resolution of demyelinating disorders such as multiple sclerosis (MS). Sensitive biomarkers of myelin synthesis are necessary for monitoring the in vivo response to candidate remyelinating agents. KineMed’s proprietary technology platform will be used to discover biomarkers that will allow EMD Serono to track and monitor rates of myelin breakdown and repair in the living brain. The synthesis of several myelin lipids and protein components, including cholesterol, galactocerebroside and phospholipids, as well as major myelin proteins, will be measured during periods of demyelination and remyelination in animal models. These measurements will be made by use of KineMed’s proprietary Dynamic Proteomics and lipid synthesis technologies. This study will also utilize KineMed’s recently developed non-invasive translational marker of brain cholesterol synthesis, which measures synthesis of brain-specific 24-hydroxy-cholesterol in the blood to better understand temporal changes in brain cholesterol synthesis relevant to MS.
About KineMed, Inc.
KineMed is a commercial-stage company focused on applying its proprietary biomarker platform technology to drug development, prescription and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests.
KineMed’s diagnostic biomarker tests directly measure the biological processes that cause disease by revealing the flux, or rate of production and destruction, over a period of time, of the key molecules involved in these biological processes. KineMed believes that measuring molecular fluxes can provide interpretable information that may be predictive for clinically meaningful endpoints for a particular patient and are designed to reveal personalized information for a patient that can guide healthcare decisions. As a result, KineMed believes KineMed’s biomarkers have the potential to have a transformative effect on healthcare by providing information that can be used to make drug development more efficient, and guide healthcare decisions by physicians and wellness decisions by consumers. Building on a legacy of collaborative relationships and experience performing biomarker tests in human disease research and drug development settings, KineMed is currently focused on commercializing biomarker tests in six areas: muscle biology, fibrotic diseases, neurodegenerative diseases, cardiometabolic diseases, skincare and cancer. KineMed’s muscle biology program represents its most advanced initiative that focuses its proprietary technology on a long-standing need in medicine and wellness management.
For more information about KineMed, please visit: www.kinemed.com